Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “C3 (Complement Component 3) Glomerulopathy”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)Looking for participantsNCT06419205
What this trial is testing

Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Who this might be right for
IgA NephropathyLupus Nephritis (LN)C3 (Complement Component 3) Glomerulopathy
Akebia Therapeutics 30
Large-scale testing (Phase 3)Looking for participantsNCT04817618
What this trial is testing

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Who this might be right for
C3G
Novartis Pharmaceuticals 98
Large-scale testing (Phase 3)Study completedNCT05067127
What this trial is testing

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc. 124
Early research (Phase 1)Study completedNCT03316521
What this trial is testing

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Who this might be right for
Complement Mediated Diseases
Amyndas Pharmaceuticals S.A. 50
Testing effectiveness (Phase 2)Ended earlyNCT02682407
What this trial is testing

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Who this might be right for
IgANLNMN+1 more
Omeros Corporation 31
Not applicableApproved For MarketingNCT04729062
What this trial is testing

C3G/Primary IC-MPGN EAP

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Study completedNCT04572854
What this trial is testing

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Who this might be right for
C3GIC-MPGNRenal Transplant+9 more
Apellis Pharmaceuticals, Inc. 13
Large-scale testing (Phase 3)Active Not RecruitingNCT05809531
What this trial is testing

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc. 100